A cell-free approach to accelerate the study of protein-protein interactions in vitro

Interface Focus

Volumn 3, Issue 5, 2013, Pages

  Sierecki, E ^a   Giles, N ^a   Polinkovsky, M ^a   Moustaqil, M ^a   Alexandrov, K ^a   Gambin, Y ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Alphascreen; Drug discovery; In vitro protein expression; Protein protein interactions; Single molecule fluorescence

Indexed keywords

EID: 84883241629     PISSN: 20428898     EISSN: 20428901     Source Type: Journal    
DOI: 10.1098/rsfs.2013.0018     Document Type: Review

References (55)

1. Fletcher S, Hamilton AD. 2007 Protein-protein interaction inhibitors: small molecules from screening techniques. Curr. Top. Med. Chem. 7, 922 -927. (doi:10.2174/156802607780906735)
2. Vassilev LT et al. 2004 In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848. (doi:10.1126/science. 1092472)
3. Galatin PS, Abraham DJ. 2004 A nonpeptidic sulfonamide inhibits the p53-MDM2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 47, 4163-4165. (doi:10.1021/jm034182u)
4. Shangary S et al. 2008 Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol. Cancer Ther. 7, 1533-1542. (doi:10.1158/1535-7163.MCT-08-0140)
5. Ding J, Zhang Y, Zheng J. 2008 Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. Curr. Cancer Drug Targets 11, 987-994.
6. Zhuang C et al. 2012 Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. J. Med. Chem. 55, 9630-9642. (doi:10.1021/jm300969t)
7. Millard M, Pathania D, Grande F, Xu S, Neamati N. 2011 Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Curr. Pharm. Des. 17, 536-559. (doi:10.2174/13816121179 5222649)
8. Vu BT, Vassilev L. 2011 Small-molecule inhibitors of the p53-MDM2 interaction. Curr. Top. Microbiol. Immunol. 348, 151-172. (doi:10.1007/ 82_2010_110)
9. Muller PA, Vousden KH. 2013 p53 mutations in cancer. Nat. Cell Biol. 15, 2-8. (doi:10.1038/ ncb2641)
10. Miliani de Marval PL, Zhang Y. 2011 The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2, 234-238.
11. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992 The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245. (doi:10.1016/0092-8674(92)90644-R)
12. Andreeff M et al. 2011 A multi-center, open-label, phase I study of single agent RG7112, a first in class p53-MDM2 antagonist, in patients with relapsed/ refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/ SCLL). In 53rd ASH Annual Meeting and Exposition, New Orleans, LA.
13. Andreeff M et al. 2012 Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist, in acute leukemia. In 54th ASH Annual Meeting and Exposition, Atlanta, GA.
14. Daniels JS, Pourmand N. 2007 Label-free impedance biosensors: opportunities and challenges. Electroanalysis 19, 1239 -1257. (doi:10.1002/elan. 200603855)
15. Jameson DM, Ross JA. 2010 Fluorescence polarization/anisotropy in diagnostics and imaging. Chem. Rev. 110, 2685 -2708. (doi:10.1021/ cr900267p)
16. Gradinaru CC, Marushchak DO, Samim M, Krull UJ. 2010 Fluorescence anisotropy: from single molecules to live cells. Analyst 135, 452-459. (doi:10.1039/ b920242k)
17. Kenworthy AK. 2001 Imaging protein-protein interactions using fluorescence resonance energy transfer microscopy. Methods 24, 289-296. (doi:10. 1006/meth.2001.1189)
18. Yan Y, Marriott G. 2003 Analysis of protein interactions using fluorescence technologies. Curr. Opin. Chem. Biol. 7, 635-640. (doi:10.1016/j.cbpa. 2003.08.017)
19. Degorce F, Card A, Soh S, Trinquet E, Knapik GP, Xie B. 2009 HTRF: a technology tailored for drug discovery: a review of theoretical aspects and recent applications. Curr. Chem. Genomics 3, 22-32. (doi:10.2174/1875397300903010022)
20. Barnard E, McFerran N, Trudgett A, Nelson J, Timson DJ. 2008 Development and implementation of split-GFP-based bimolecular fluorescence complementation (BiFC) assays in yeast. Biochem. Soc. Trans. 36(Pt 3), 479-482. (doi:10.1042/ BST0360479)
21. Hu C-D, Kerppola TK. 2003 Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis. Nat. Biotech. 21, 539-545. (doi:10.1038/nbt816)
22. Kerppola TK. 2008 Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells. Annu. Rev. Biophys. 37, 465-487. (doi:10.1146/annurev. biophys.37.032807.125842)
23. Michnick SW, Ear PH, Manderson EN, Remy I, Stefan E. 2007 Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat. Rev. Drug Discov. 6, 569-582. (doi:10.1038/nrd2311)
24. Ghai R, Falconer RJ, Collins BM. 2012 Applications of isothermal titration calorimetry in pure and applied research: survey of the literature from 2010. J. Mol. Recognit. 25, 32-52. (doi:10.1002/jmr.1167)
25. Ladbury JE. 2010 Calorimetry as a tool for understanding biomolecular interactions and an aid to drug design. Biochem. Soc. Trans. 38, 888-893. (doi:10.1042/BST0380888)
26. Jason-Moller L, Murphy M, Bruno J. 2001 Overview of Biacore systems and their applications. In Current protocols in protein science. London, UK: John Wiley & Sons Inc. (doi:10.1002/0471140864.ps1913s45)
27. Nedelkov D, Nelson RW. 2003 Surface plasmon resonance mass spectrometry: recent progress and outlooks. Trends Biotechnol. 21, 301-305. (doi:10. 1016/S0167-7799(03)00141-0)
28. McGuinness R. 2007 Impedance-based cellular assay technologies: recent advances, future promise. Curr. Opin. Pharmacol. 7, 535-540. (doi:10.1016/j.coph. 2007.08.004)
29. Ohuchi S, Nakano H, Yamane T. 1998 In vitro method for the generation of protein libraries using PCR amplification of a single DNA molecule and coupled transcription/translation. Nucleic Acids Res. 26, 4339-4346. (doi:10.1093/nar/26.19.4339)
30. Goerke AR, Swartz JR. 2009 High-level cell-free synthesis yields of proteins containing site-specific non-natural amino acids. Biotechnol. Bioeng. 102, 400-416. (doi:10.1002/bit.22070)
31. Saraogi I, Zhang D, Chandrasekaran S, Shan S. 2011 Site-specific fluorescent labeling of nascent proteins on the translating ribosome. J. Am. Chem. Soc. 133, 14 936-14 939. (doi:10.1021/ja206626g)
32. Nirenberg MW, Matthaei JH. 1961 The dependence of cell-free protein synthesis in E. coli upon naturally occurring or synthetic polyribonucleotides. Proc. Natl Acad. Sci. USA 47, 1588-1602. (doi:10. 1073/pnas.47.10.1588)
33. Katzen F, Chang G, Kudlicki W. 2005 The past, present and future of cell-free protein synthesis. Trends Biotechnol. 23, 150-156. (doi:10.1016/j. tibtech.2005.01.003)
34. Swartz J. 2006 Developing cell-free biology for industrial applications. J. Ind. Microbiol. Biotechnol. 33, 476-485. (doi:10.1007/s10295-006-0127-y)
35. Goerke AR, Swartz JR. 2008 Development of cell-free protein synthesis platforms for disulfide bonded proteins. Biotechnol. Bioeng. 99, 351 -367. (doi:10. 1002/bit.21567)
36. Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, Levy R. 2007 Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood 109, 3393-3399. (doi:10.1182/blood-2006-07-030593)
37. Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, Gold DS, Heinsohn HG, Murray CJ. 2011 Microscale to manufacturing scale-up of cell-free cytokine production: a new approach for shortening protein production development timelines. Biotechnol. Bioeng. 108, 1570-1578. (doi:10.1002/ bit.23103)
38. Goshima N et al. 2008 Human protein factory for converting the transcriptome into an in vitro- expressed proteome. Nat. Methods 5, 1011-1017. (doi:10.1038/nmeth.1273)
39. Griffiths AD, Tawfik DS. 2003 Directed evolution of an extremely fast phosphotriesterase by in vitro compartmentalization. EMBO J. 22, 24-35. (doi:10. 1093/emboj/cdg014)
40. Wang X et al. 2008 An optimized yeast cell-free system: sufficient for translation of human papillomavirus 58 L1 mRNA and assembly of virus-like particles. J. Biosci. Bioeng. 106, 8-15. (doi:10.1263/jbb.106.8)
41. Mureev S, Kovtun O, Nguyen UTT, Alexandrov K. 2009 Species-independent translational leaders facilitate cell-free expression. Nat. Biotech. 27, 747-752. (doi:10.1038/nbt.1556)
42. Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bossé R, Bielefeld M. 2008 The use of AlphaScreen technology in HTS: current status. Curr. Chem. Genomics 1, 2-10. (doi:10.2174/1875397300801010002)
43. Takahashi H, Takahashi C, Moreland NJ, Chang Y-T, Sawasaki T, Ryo A, Vasudevan SG, Suzuki Y, Yamamoto N. 2012 Establishment of a robust dengue virus NS3-NS5 binding assay for identification of protein-protein interaction inhibitors. Antiviral Res. 96, 305-314. (doi:10. 1016/j.antiviral.2012.09.023)
44. Kaur G, Delluc-Clavieres A, Poon IKH, Forwood JK, Glover DJ, Jans DA. 2010 Calmodulin-dependent nuclear import of HMG-box family nuclear factors: importance of the role of SRY in sex reversal. Biochem. J. 430, 39-48. (doi:10.1042/BJ20091758)
45. Rayter S et al. 2007 A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene 27, 1036-1044. (doi:10.1038/sj.onc. 1210729)
46. Hu G, Li X, Li Y, Sun X, Liu G, Li W, Huang J, Shen X, Tang Y. 2012 Inhibitors of HIV-1 integrase-human LEDGF/p75 interaction identified from natural products via virtual screening. Chin. J. Chem. 30, 2752-2758. (doi:10.1002/cjoc.201200897)
47. Demeulemeester J, Tintori C, Botta M, Debyser Z, Christ F. 2012 Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J. Biomol. Screen. 17, 618-628. (doi:10.1177/1087057111436343)
48. Madono M, Sawasaki T, Morishita R, Endo Y. 2011 Wheat germ cell-free protein production system for post-genomic research. New Biotechnol. 28, 211-217. (doi:10.1016/j.nbt.2010.08.009)
49. Mohamed MR et al. 2009 Proteomic screening of variola virus reveals a unique NF-kB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc. Natl Acad. Sci. USA 106, 9045-9050. (doi:10.1073/pnas.0900452106)
50. Moerner WE, Orrit M. 1999 Illuminating single molecules in condensed matter. Science 283, 1670-1676. (doi:10.1126/science.283.5408.1670)
51. Gambin Y, Deniz AA. 2010 Multicolor single-molecule FRET to explore protein folding and binding. Mol. Biosyst. 6, 1540-1547. (doi:10.1039/c003024d)
52. Ferreon AC, Gambin Y, Lemke EA, Deniz AA. 2009 Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc. Natl Acad. Sci. USA 106, 5645-5650. (doi:10.1073/pnas.0809232106)
53. Gambin Y, Schug A, Lemke EA, Lavinder JJ, Ferreon ACM, Magliery TJ, Onuchic JN, Deniz AA. 2009 Direct single-molecule observation of a protein living in two opposed native structures. Proc. Natl Acad. Sci. USA 106, 10153-10158. (doi:10.1073/pnas. 0904461106)
54. Gambin Y, VanDelinder V, Ferreon ACM, Lemke EA, Groisman A, Deniz AA. 2011 Visualizing a one-way protein encounter complex by ultrafast single-molecule mixing. Nat. Methods 8, 239-241. (doi:10.1038/nmeth.1568)
55. Gavin AC et al. 2002 Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415, 141-147. (doi:10.1038/415141a)